Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Labels

March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
rareconnect.org TMAU

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :
https://forms.gle/vem2TjepKobYZPBu8

current participants : 113 (update 18dec20)

Wednesday, March 29, 2017

Presentation Topics MEBO Conference 2017

The Betsy South Beach
I hope to see many of you at the MEBO Annual Meetup/Conference 2017 this coming Friday at the,

The Betsy South Beach
1440 Ocean Drive
Miami Beach, Fl 33139
866 79-BETSY (866 782 3879)

March 31, 2017
8:00 p.m. to 11 p.m.
In hotel Library
Desert, coffee and tea will be served

The following are the Presentation Topics for the conference:
  1. Professor Elizabeth Shephard, Ph.D., has done a video presentation on "Gut microbiome and diet." It covers a significant amount of information, such as,
    • Explains what is microbiome and where found on our bodies,
    • Its function: Feeds us, forms us, and protects us.
    • How do we acquire a microbiome?
    • Primary TMAU - FMO3, Diet and microbiome,
    • Multiple microbiome-mediated pathways can lead to TMA production,
    • Fish diet
    MEBO and Dr. Wishart and his staff will hold a conference call to determine the direction we should take with the study as we move forward.
  2. RESULTS of The MEBO Metabolomic Profiling Pilot Study, NCT02683876, registered with the U.S. Clinical Trials.gov., Dr Gabashvilli is the registered U.S. Principal Investigator of this study in collaboration with the other registered Principal Investigator, David Wishart, Ph.D., and his staff at the Metabolomics Innovation Center (TMIC) of the University of Alberta, in Edmonton, Canada.

    The great news is that...the study will remain live.
    Thankfully, Dr. David Wishart's Metabolomic Innovation Centre at the University of Alberta, Canada, has given us the results of the pilot study of the MEBO Metabolomic Study on March 24th, exactly 7 days prior to the conference. Consequently, MEBO's Scientific Director is still working ardently on interpreting the results and creating a presentation for us of these results.

    The great news is that Dr. Wishart recommends that we need to do other assays to find out any meaningful observation. After I return from the meetup/conference and cruise, MEBO and Dr. Wishart and his staff will hold a conference call to determine the direction we should take with the study as we move forward. It is now expected that the study will remain live.
  3. "Metabolic pathway simulations, Apocrine Bromhidrosis compared to Trimethylaminuria, The new support of research by high throughput simulations backed by large enzyme databases" Video presentation.

    Topics of this presentation:
    1. Fecal (indole) breath and body odor and it's recommended supplementation and diet,
    2. Apocrine and eccrine sweat glands metabolic disease in Bromhidrosis,
      • Discussions on isovaleric acid and amino acid leucine in eccrine bromhidrosis,
      • Thyroid functions with and without elevated TSH and recommended supplementation and diet.
  4. This very interesting presentation raises question on whether TMAU2 to TMAU1 relation pattern could be transferred to the Bromhidrosis pattern as well.

María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
www.mebo.com.br/
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)



SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.


get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

0 comments:

Post a Comment